Pharming Group reported second-quarter revenue of $90.2 million, a three percent decrease from the same period last year [1].

The results highlight a shift in the company's product portfolio performance. While one key therapy is seeing a decline in market traction, a newer treatment is beginning to stabilize the company's top line.

The Pharming Group CEO said revenue was $90.2 million, down three percent from a year earlier [1]. The company, which trades on the NASDAQ under the ticker PHAR, is navigating a transition between its primary revenue drivers.

The decline was primarily driven by lower sales of RUCONEST, a therapy used to treat hereditary angioedema [1]. This loss of momentum in the RUCONEST line created a drag on the overall quarterly performance.

However, the company found a partial hedge against these losses through its Joenja treatment. The Pharming Group CFO said that Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST [1]. This suggests that the adoption of Joenja is scaling up as the company manages the lifecycle of its older therapies.

Financial analysts are monitoring how quickly the growth of Joenja can outpace the decline of RUCONEST. The company's ability to maintain its market position depends on this balance, ensuring that new product success compensates for the erosion of legacy revenue streams.

“Revenue was $90.2 million, down 3% from a year earlier.”

The slight revenue dip indicates a volatile transition period for Pharming Group. The company is relying on the growth of Joenja to replace the dwindling income from RUCONEST. If Joenja fails to accelerate its growth, the company may face further revenue contractions in subsequent quarters.